Ramucirumab for DSRCT (J1S-MC-JV01)
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor (CAMPFIRE)
Rekrutierung beendet
Summary
This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory desmoplastic small round cell tumor (DSRCT) in children and young adults (12 months to 29 years).
Ramucirumab is a monoclonal antibody designed to attach to vascular endothelial growth factor receptor (VEGFR), a protein present at high levels in tumours. VEGFR helps the development of new blood vessels that supply the tumour. By attaching to VEGFR, ramucirumab blocks this action, reducing the blood supply to the tumour and so slowing the growth of the cancer.
Ramucirumab is given intravenously, Cyclophosphamide is given orally and vinorelbine intravenously.
Main inclusion criteria
- Pediatric patients and young adults (12 months - 29 years)
- Patients with relapsed, recurrent, or refractory DSRCT
- measurable disease by RECIST criteria
Sponsor
Eli Lilly